WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting ...

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting ...

Core Viewpoint - Tevogen Bio Holdings Inc. is transitioning from a biotechnology innovator to a dynamic enterprise that integrates artificial intelligence into its operations, aiming to deliver impactful and affordable therapies through advanced science and technology [1][2]. Company Developments - Tevogen has validated its proprietary ExacTcell™ platform and completed a successful proof-of-concept clinical trial for its first product, while also establishing a drug discovery R&D center and working on a GMP cell manufacturing facility [2]. - The company has built a robust intellectual property portfolio and initiated one of the pioneering AI initiatives in the industry, maintaining a 74% insider equity ownership [2][7]. AI Integration - The launch of the AI-driven PredicTcell™ platform has significantly improved target discovery efficiency, supported by strategic partnerships with technology leaders like Microsoft and Databricks [3]. - Recent patent filings have further secured Tevogen's intellectual property in AI-driven predictive modeling, positioning the company at the forefront of innovation [3]. Financial Position - Tevogen is well-capitalized and has access to necessary funding to execute its growth strategy, including the accelerated development of Tevogen.AI [4]. - The company has observed drastic time reductions in target analysis, translating to potential savings of billions in drug development costs [7]. Corporate Structure - Tevogen's new headquarters, fully funded by the CEO, centralizes R&D and AI teams to enhance innovation [7].